EGFR and pancreatic neoplasm: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for use in NSCLC in 2004 and pancreatic cancer in 2005 (Carter and Tadi, 2025).